{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "folate receptor \u03b1",
      "ovarian cancer",
      "peritoneal carcinomatosis",
      "prophylactic photodynamic therapy",
      "targeted therapy"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25532689",
  "DateCompleted": {
    "Year": "2015",
    "Month": "03",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2014",
    "Month": "12",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "10.1684/bdc.2014.1977"
    ],
    "Journal": {
      "ISSN": "1769-6917",
      "JournalIssue": {
        "Volume": "101",
        "Issue": "12",
        "PubDate": {
          "Year": "2014",
          "Month": "Dec"
        }
      },
      "Title": "Bulletin du cancer",
      "ISOAbbreviation": "Bull Cancer"
    },
    "ArticleTitle": "[FR\u03b1: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?].",
    "Pagination": {
      "StartPage": "1109",
      "EndPage": "1113",
      "MedlinePgn": "1109-13"
    },
    "Abstract": {
      "AbstractText": [
        "Partly due to delays in its diagnosis, ovarian cancer's prognosis remains dire after primary therapy. Treatment consists in complete cytoreductive surgery and platinum-based chemotherapy. Recurrence rates are disappointingly high, as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within five years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictors of recurrences. Targeted therapies aim to bring chemotherapy, radiotherapy and selective tumor photosensitizer (PS) agents to the targeted cell and its tumoral microenvironment. Folate receptor \u03b1 (FR\u03b1) shows promising prospects in targeting ovarian cancerous cells. Indeed, with good specificity and frequent overexpression in ovarian cancer, FR\u03b1 is a recurrent topic in recent publications. The aim of this review is to present FR\u03b1 and the reasons that make it an ideal targeting ligand for ovarian carcinoma therapy. Prophylactic photodynamic therapy (PPDT) using new generation FR\u03b1-coupled agents combined with complete cytoreductive surgery could allow for a significant decrease in recurrence rates. Preclinical trials are being run in order to allow for human clinical applications."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, H\u00f4pital Jeanne de Flandre, Service de gyn\u00e9cologie, 59000 Lille, France."
          }
        ],
        "LastName": "Aza\u00efs",
        "ForeName": "Henri",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Lorraine, UMR 7274 CNRS, Laboratoire r\u00e9actions et g\u00e9nie des proc\u00e9d\u00e9s, 54000 Nancy, France."
          }
        ],
        "LastName": "Moussaron",
        "ForeName": "Albert",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, H\u00f4pital Jeanne de Flandre, Service de gyn\u00e9cologie, 59000 Lille, France."
          }
        ],
        "LastName": "Khodja Bach",
        "ForeName": "Soraya",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, H\u00f4pital Jeanne de Flandre, Service de gyn\u00e9cologie, 59000 Lille, France."
          }
        ],
        "LastName": "Bassil",
        "ForeName": "Alfred",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France."
          }
        ],
        "LastName": "Betrouni",
        "ForeName": "Nacim",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Lorraine, UMR 7274 CNRS, Laboratoire r\u00e9actions et g\u00e9nie des proc\u00e9d\u00e9s, 54000 Nancy, France."
          }
        ],
        "LastName": "Frochot",
        "ForeName": "C\u00e9line",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, H\u00f4pital Jeanne de Flandre, Service de gyn\u00e9cologie, 59000 Lille, France."
          }
        ],
        "LastName": "Collinet",
        "ForeName": "Pierre",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHRU de Lille, Unit\u00e9 Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France."
          }
        ],
        "LastName": "Mordon",
        "ForeName": "Serge",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ],
    "VernacularTitle": "FR\u03b1\u00a0: une cible pour la th\u00e9rapie photodynamique prophylactique des m\u00e9tastases p\u00e9riton\u00e9ales ovariennes\u00a0?"
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Bull Cancer",
    "NlmUniqueID": "0072416",
    "ISSNLinking": "0007-4551"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Folate Receptor 1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Photosensitizing Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Porphyrins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "tetraphenylporphyrin"
    },
    {
      "RegistryNumber": "935E97BOY8",
      "NameOfSubstance": "Folic Acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Folate Receptor 1"
    },
    {
      "QualifierName": [
        "chemistry",
        "therapeutic use"
      ],
      "DescriptorName": "Folic Acid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "chemistry",
        "pathology"
      ],
      "DescriptorName": "Ovarian Neoplasms"
    },
    {
      "QualifierName": [
        "prevention & control",
        "secondary"
      ],
      "DescriptorName": "Peritoneal Neoplasms"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Photochemotherapy"
    },
    {
      "QualifierName": [
        "chemistry",
        "therapeutic use"
      ],
      "DescriptorName": "Photosensitizing Agents"
    },
    {
      "QualifierName": [
        "chemistry",
        "therapeutic use"
      ],
      "DescriptorName": "Porphyrins"
    }
  ]
}